Viking Therapeutics, Inc. (VKTX)
| Market Cap | 2.69B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -109.96M |
| Shares Out | 112.25M |
| EPS (ttm) | -1.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,042,405 |
| Open | 22.00 |
| Previous Close | 23.60 |
| Day's Range | 21.26 - 24.12 |
| 52-Week Range | 18.92 - 81.86 |
| Beta | 0.83 |
| Analysts | Strong Buy |
| Price Target | 89.75 (+276.63%) |
| Earnings Date | Apr 23, 2025 |
About VKTX
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company’s lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for VKTX stock is "Strong Buy." The 12-month stock price forecast is $89.75, which is an increase of 276.63% from the latest price.
News
Viking Therapeutics: A Lot More Compelling After The Meltdown - Initiating Cautious Buy (Rating Upgrade)
VKTX's deep selloff from the 2024 heights have been well warranted indeed, given its pre-revenue status and ongoing cash burn, despite the promising GLP-1 candidates. It has also triggered the improve...
Viking Therapeutics: Trading The Volatility Of The Weight Loss Drug Market
Viking Therapeutics, Inc. stock has dropped ~35% amid market volatility, but Pfizer's withdrawal of danuglipron boosts VK2735's prospects as a leading oral GLP-1 for obesity. Goldman Sachs' Neutral ra...
Will Pfizer approach Viking Therapeutics with a buyout proposal?
Investors are running into Viking Therapeutics (NASDAQ: VKTX) this week after an incident of drug-induced liver injury pushed Pfizer (NYSE: PFE) into terminating the development of its weight-loss pil...
Viking Therapeutics' VK2735 Candidate Likely Boosted By Pfizer's Woes
13-week data from the Viking Therapeutics, Inc. phase 2 VENTURE-Oral Dosing trial using oral VK2735 for the treatment of patients with obesity, expected 2nd half of 2025. Pfizer's recent setbacks in w...
What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday?
Viking Therapeutics, Inc. VKTX, Eli Lilly And Co LLY and Novo Nordisk A/S NVO stocks are trading higher on Monday.
Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
13-Week Study Evaluating the Safety and Efficacy of Oral VK2735 Dosed Once Daily Results Expected in 2H25 SAN DIEGO , March 26, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX)...
Viking Therapeutics: No Buyout Needed Now
Viking Therapeutics' hit yearly lows despite strong sector expectations, as it enters pivotal trials for obesity drugs. The biotech announced a production deal with CordenPharma, signaling confidence ...
Viking Therapeutics' new contract is a game changer. Here's how much money it could bring in.
Viking has found a manufacturing partner, removing a key overhang on the stock.
Viking Therapeutics Is Ready For A Standalone Future
Viking Therapeutics announced a supply deal with CordenPharma that sets it up for a standalone path to the obesity market. The deal covers a substantial supply of both the subcutaneous and oral VK2735...
Viking Therapeutics: Finally, Here Comes The Buying Opportunity (Upgrade)
The sell-off in unprofitable stocks has hit tech and growth sectors hard, with investors seeking safety in healthcare and consumer staples. Viking Therapeutics remains speculative despite progress in ...
Viking Therapeutics Signs Broad Manufacturing Agreement With CordenPharma to Support Commercialization of VK2735
Long-Term Agreement Secures Dedicated Capacity for Multi-Ton Annual Supply of VK2735 Active Pharmaceutical Ingredient Secures Dedicated Fill/Finish Capacity for 100 Million Annual Autoinjector Supply ...
Viking Therapeutics: Signs Of Insufficient Differentiation In Obesity Treatment (Rating Downgrade)
Viking Therapeutics' stock declined by 37% following a downgrade to "hold" in December, anticipating competitive pressures from Novo Nordisk's CagriSema Phase 3 results. The company's GIP/GLP-1 agonis...
Stock Picks From Seeking Alpha's February 2025 New Analysts
In February, twenty-three new analysts joined Seeking Alpha, offering diverse stock picks and insights, from biotech to automotive and energy sectors. Analysts provided ratings from Strong Sell to Str...
Viking Therapeutics to Participate at Upcoming Investor Conferences
SAN DIEGO , March 4, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic an...
Viking Therapeutics: Development Of VK2735 Continues, Buyout Or Not
Viking Therapeutics: Development Of VK2735 Continues, Buyout Or Not
Viking Therapeutics, Inc. (VKTX) Q4 2024 Earnings Conference Call Transcript
Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2024 Earnings Conference Call February 5, 2025 4:30 PM ET Company Participants Stephanie Diaz - IR Manager Brian Lian - CEO and President Greg Zante - CFO C...
Viking Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update
Conference call scheduled for 4:30 p.m. ET today Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25 Phase 2 VENTURE-Oral Dosing Trial Evaluating VK2735 in Obesity Under...
Viking Therapeutics: Why The Oral VK2735 Phase 2 Readout Could Send The Stock Soaring
Oral VK2735 is strategically positioned to become a best-in-class oral GLP-1 therapy, with the Phase 2 trial data readout in H2 2025 serving as a critical catalyst. Phase 1 data for VK2735 represents ...
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2024 on February 5, 2025
Conference Call Scheduled for Wednesday, February 5 at 4:30 p.m. Eastern Time SAN DIEGO , Jan. 29, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharma...
Viking Therapeutics: Investors Meeting Reality Of The Obesity Market
Viking Therapeutics has promising clinical developments in obesity, NASH/MASH, and X-ALD, but its stock fell 50% due to broader GLP-1 market concerns. Despite Eli Lilly's Q4 miss, the long-term outloo...
Why this Weight-Loss Drug Stock Could Gain 200%
There are several potential challengers to Novo Nordisk and Eli Lilly's obesity drugs, and Jefferies analysts see one as particularly promising.
Top 3 Health Care Stocks That Could Blast Off This Quarter
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
What's next for Viking Therapeutics? Here's how the company can scale up.
Viking's obesity-drug program is progressing well. Now management is thinking about manufacturing tie-ups.
3 Oversold Biotech Names
High beta market sectors, including small caps and biotech, sold off significantly last week as the 10-Year Treasury yield surpassed 4.75%. The JP Morgan Healthcare event in San Francisco that opens t...
Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
13-Week Study to Evaluate the Safety and Efficacy of Oral VK2735 Dosed Once Daily SAN DIEGO , Jan. 8, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biophar...